Abstract: A pharmaceutical composition comprising an effective amount of Dacomitinib as epidermal growth factor receptor (EGFR) inhibitor and a prostaglandin-Endoperoxide Synthase 2 (PTGS2) inhibitor, and one or more pharmaceutically acceptable excipients. A pharmaceutical composition comprising an effective amount of Dacomitinib as epidermal growth factor receptor (EGFR) inhibitor and an Adrenoceptor Beta 2 (ADRB2) inhibitor, and one or more pharmaceutically acceptable excipients. A method of treating pancreatic cancer, the method comprising the step of administering a therapeutically effective amount of the pharmaceutical composition to an individual in need thereof, the pharmaceutical composition comprising an effective amount of Dacomitinib as epidermal growth factor receptor (EGFR) inhibitor with a prostaglandin-Endoperoxide Synthase 2 (PTGS2) inhibitor or an Adrenoceptor Beta 2 (ADRB2) inhibitor, and one or more pharmaceutically acceptable excipients.

Abstract: The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.

Abstract: An automobile antenna assembly including a housing adapted for installation on a roof of an automobile, the housing having a base portion and a fin portion extending from the base portion, a radio antenna disposed within the fin portion, and a photo radiation intensity sensor disposed within the base portion, the photo radiation intensity sensor including a first light detecting element located on a first side of the fin portion and a second light detecting element located on a second side of the fin portion opposite the first side, wherein at least a portion of the base portion is translucent for allowing light to be received by the first and second light detecting elements, the fin portion providing a light barrier between the first light detecting element and the second light detecting element.

Abstract: A radar-based occupancy detection system that includes a seatbelt buckle disposed adjacent a seat of a vehicle and a radar module disposed within the seatbelt buckle, the radar module including an antenna, a radio frequency (RF) transmitter, a RF receiver, and a processor, the antenna configured to broadcast a RF signal generated by the RF transmitter toward the seat, the processor configured to derive signal information from output received from the receiver and to characterize occupancy of the seat based on the signal information.

Abstract: An automobile antenna assembly including a housing adapted for installation on a roof of an automobile, the housing having a base portion and a fin portion extending from the base portion, a radio antenna disposed within the fin portion, and a photo radiation intensity sensor disposed within the base portion, the photo radiation intensity sensor including a first light detecting element located on a first side of the fin portion and a second light detecting element located on a second side of the fin portion opposite the first side, wherein at least a portion of the base portion is translucent for allowing light to be received by the first and second light detecting elements, the fin portion providing a light barrier between the first light detecting element and the second light detecting element.

Abstract: An automobile antenna assembly including a housing adapted for installation on a roof of an automobile, the housing having a base portion and a fin portion extending from the base portion, a radio antenna disposed within the fin portion, and a photo radiation intensity sensor disposed within the base portion, the photo radiation intensity sensor including a first light detecting element located on a first side of the fin portion and a second light detecting element located on a second side of the fin portion opposite the first side, wherein at least a portion of the base portion is translucent for allowing light to be received by the first and second light detecting elements, the fin portion providing a light barrier between the first light detecting element and the second light detecting element.

Abstract: An exemplary embodiment of active/passive automotive fuse module in accordance with the present disclosure may include an electrically insulating base, a fuse plate including a bus bar portion disposed on a top surface of the base above a projectile cavity formed in the base, the fuse plate further including a fusible portion electrically connected to the bus bar portion and adapted to open when an amount of current flowing through the fuse plate exceeds a current rating of the active/passive automotive fuse module, the active/passive automotive fuse module further including a pyrotechnic interrupter (PI) disposed atop the base and including a projectile positioned above the bus bar portion, the PI configured to drive the projectile through the bus bar portion upon actuation of the PI.

Abstract: A method for determining combination drug and use in pancreatic cancer treatment, includes retrieving Pancreatic cancer datasets from a plurality of data sources based on selected types of expression profiling. A set of feature genes is determined based on differential gene expression analysis of disease samples and control samples in normalized pancreatic cancer datasets. Pancreatic cancer targets are selected for combination analysis based on druggability and determined set of feature genes. Based on node embedded clustering of the selected pancreatic cancer targets, synergistic target pairs is determined. Candidate pairs of drug combinations are selected from a plurality of pairs of drug combinations based on cumulative ranking score of each pair of drug combination and the synergistic target pairs.

Abstract: A method for evaluating potential drug compositions for a target disease. The method includes providing a data input to a discovery engine, using the discovery engine to identify a first set of potential drug compositions for the target disease. The discovery engine is configured to analyze failed clinical assets of drugs for the target disease, wherein the discovery engine filters clinical trials which have failed due to non-drug safety related issues, perform differential gene expression analysis on normalized target-disease-related data, evaluate effect of known drugs used for diseases similar to the target disease, and perform a network-based analysis to identify repurposable drugs. Furthermore, asset prioritization is used to filter the first set of potential drug compositions to determine at least one potential drug composition for the target disease and validating the at least one potential drug composition for the target disease based on biological evidence and differential expression analysis.

Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.

Abstract: A fuse including a fuse body, a fusible element disposed within the fuse body providing an electrically conductive pathway extending between a first end of the fuse body and a second end of the fuse body, and a heat shield disposed within the fuse body intermediate an interior surface of the fuse body and an exterior surface of the fuse body for mitigating heat flow therebetween.

Abstract: An automobile antenna assembly including a housing adapted for installation on a roof of an automobile, the housing having a base portion and a fin portion extending from the base portion, a radio antenna disposed within the fin portion, and a photo radiation intensity sensor disposed within the base portion, the photo radiation intensity sensor including a first light detecting element located on a first side of the fin portion and a second light detecting element located on a second side of the fin portion opposite the first side, wherein at least a portion of the base portion is translucent for allowing light to be received by the first and second light detecting elements, the fin portion providing a light barrier between the first light detecting element and the second light detecting element.

Abstract: An exemplary embodiment of active/passive automotive fuse module in accordance with the present disclosure may include an electrically insulating base, a fuse plate including a bus bar portion disposed on a top surface of the base above a projectile cavity formed in the base, the fuse plate further including a fusible portion electrically connected to the bus bar portion and adapted to open when an amount of current flowing through the fuse plate exceeds a current rating of the active/passive automotive fuse module, the active/passive automotive fuse module further including a pyrotechnic interrupter (PI) disposed atop the base and including a projectile positioned above the bus bar portion, the PI configured to drive the projectile through the bus bar portion upon actuation of the PI.

Abstract: The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.

Abstract: A radar-based occupancy detection system that includes a seatbelt buckle disposed adjacent a seat of a vehicle and a radar module disposed within the seatbelt buckle, the radar module including an antenna, a radio frequency (RF) transmitter, a RF receiver, and a processor, the antenna configured to broadcast a RF signal generated by the RF transmitter toward the seat, the processor configured to derive signal information from output received from the receiver and to characterize occupancy of the seat based on the signal information.

Abstract: The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.

Abstract: The present invention relates to a glucocorticoid (GC) for use in the amelioration, treatment or prophylaxis of neurological/psychiatric adverse events caused by a CD3 binding domain. Kits comprising a GC, a CD3 binding domain and instructions for use which indicate that the GC is to be employed for the treatment amelioration and/or prophylaxis of neurological adverse events caused by said CD3 binding domain, are also disclosed.

Abstract: The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.

Abstract: The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20×CD3 or a CD19×CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment.

Abstract: The present invention relates to a pentosanpolysulfate (PPS) or a pharmaceutically acceptable salt thereof for use in the amelioration, treatment, or prevention of adverse neurological events caused by administering an antibody or fragment thereof comprising a CD3 binding domain, including a CD19 x CD3 bispecific single chain antibody, such as blinatumomab. PPS is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. Kits comprising a PPS, an antibody or fragment thereof comprising a CD3 binding domain, and instructions for administration, which indicate that the PPS is to be employed for the amelioration, treatment or prevention of adverse neurological events caused by administering the antibody or fragment thereof comprising said CD3 binding domain, are also disclosed.